| TSBP1-AS1 |
|
TSBP1 and BTNL2 antisense RNA 1
|
|
|
0.638 |
0.692 |
| HLA-DRB9 |
|
major histocompatibility complex, class II, DR beta 9 (pseudogene)
|
|
|
0.682 |
0.654 |
| HCP5 |
Q6MZN7
|
HLA complex P5
|
|
|
0.595 |
0.808 |
| LINC02571 |
|
long intergenic non-protein coding RNA 2571
|
|
|
0.743 |
0.500 |
| LINC00824 |
|
long intergenic non-protein coding RNA 824
|
|
|
0.695 |
0.346 |
| LINC00243 |
|
long intergenic non-protein coding RNA 243
|
|
|
0.729 |
0.423 |
| MSH5-SAPCD1 |
|
MSH5-SAPCD1 readthrough (NMD candidate)
|
|
|
0.760 |
0.423 |
| ZNRD1ASP |
|
zinc ribbon domain containing 1 antisense, pseudogene
|
|
|
0.691 |
0.538 |
| HCG17 |
|
HLA complex group 17
|
|
|
0.769 |
0.346 |
| HCG18 |
|
HLA complex group 18
|
|
|
0.722 |
0.538 |
| ATP6V1G2-DDX39B |
|
ATP6V1G2-DDX39B readthrough (NMD candidate)
|
|
|
0.769 |
0.423 |
| DRAIC |
|
downregulated RNA in cancer, inhibitor of cell invasion and migration
|
|
|
0.736 |
0.423 |
| EHMT2-AS1 |
|
EHMT2 and SLC44A4 antisense RNA 1
|
|
|
0.780 |
0.462 |
| AP4B1-AS1 |
|
AP4B1 antisense RNA 1
|
|
|
0.805 |
0.231 |
| PPT2-EGFL8 |
|
PPT2-EGFL8 readthrough (NMD candidate)
|
|
|
0.792 |
0.462 |
| LINC01185 |
|
long intergenic non-protein coding RNA 1185
|
|
|
0.743 |
0.346 |
| LINC01934 |
|
long intergenic non-protein coding RNA 1934
|
|
|
0.821 |
0.308 |
| HCG9 |
|
HLA complex group 9
|
|
|
0.700 |
0.500 |
| HCG22 |
E2RYF7
|
HLA complex group 22 (gene/pseudogene)
|
|
|
0.736 |
0.423 |
| C2-AS1 |
|
C2 antisense RNA 1
|
|
|
0.821 |
0.192 |
| LINC02357 |
|
long intergenic non-protein coding RNA 2357
|
|
|
0.805 |
0.231 |
| LINC02649 |
|
long intergenic non-protein coding RNA 2649
|
|
|
0.792 |
0.308 |
| LINC01104 |
|
long intergenic non-protein coding RNA 1104
|
|
|
0.805 |
0.115 |
| HLA-DPB2 |
|
major histocompatibility complex, class II, DP beta 2 (pseudogene)
|
|
|
0.743 |
0.500 |
| HLA-DPA2 |
|
major histocompatibility complex, class II, DP alpha 2 (pseudogene)
|
|
|
0.780 |
0.538 |